Physician profile
David A Lee
NPI 1285048702
$2,675.49
in general payments reported to CMS, 2019-2025
26 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $588 · 2022: $823 · 2023: $587 · 2024: $323 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $757.04 | 2022-2025 | Proclaim |
| Abbvie INC. | $448.97 | 2022-2024 | |
| Scilex Pharmaceuticals INC. | $339.03 | 2021-2023 | Ztlido |
| Collegium Pharmaceutical, INC. | $191.68 | 2021-2023 | Xtampza |
| Nevro Corp. | $144.65 | 2021-2022 | |
| Axsome Therapeutics, INC. | $98.12 | 2025 | Symbravo |
| Lilly USA, LLC | $89.57 | 2021-2023 | Emgality |
| Amgen INC. | $83.35 | 2021-2022 | |
| Indivior INC. | $52.61 | 2023-2024 | Sublocade |
| Arbor Pharmaceuticals, INC. | $50.11 | 2021-2022 | |
| Almatica Pharma LLC | $48.14 | 2023 | Gralise |
| Redhill Biopharma INC. | $45.53 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.68 | 2022 | |
| Braeburn INC. | $43.85 | 2025 | Brixadi |
| Forte Bio-Pharma LLC | $35.58 | 2021-2023 | Prolate, Nalocet |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $26.31 | 2021 | |
| Teleflex LLC | $22.98 | 2024 | Arrow |
| Chiesi USA, INC. | $22.78 | 2023 | Cleviprex |
| Emd Serono, INC. | $22.47 | 2021 | |
| Ibsa Pharma INC. | $19.04 | 2023 | Tirosint, Licart |
| Biodelivery Sciences International, INC. | $17.89 | 2021 | |
| Azurity Pharmaceuticals, INC. | $17.51 | 2023 | Horizant |
| Pfizer INC. | $15.07 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.40 | 2022 | |
| Fidia Pharma USA INC. | $12.09 | 2021 | |
| Eisai INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.